Abstract
Among all mental disorders, major depression has the highest rate of prevalence and incidence of morbidity. Currently available antidepressant therapies have limited efficacies; consequently, research on new drugs for the treatment of mood disorders has become increasingly critical. Recent preclinical evidences that cannabinoid agonists and endocannabinoid enhancers, such as the fatty acid amide hydrolase (FAAH) inhibitors, can impact mood regulation have opened a new line of research in antidepressant drug discovery. However, the neurobiological mechanisms linking the endocannabinoid system with the pathophysiology of mood disorders and antidepressant action remain unclarified. In this review, we have presented an update on preclinical data indicating the antidepressant potential of cannabinoid agonists and endocannabinoid enhancers in comparison to standard antidepressants. Data obtained from CB1 knockout (CB1-/-) and FAAH knockout (FAAH-/-) mice have also been examined within this context. We have illustrated how the various classes of antidepressants exert their therapeutic action. In particular, all antidepressants increase the neurotransmission of serotonin after long-term treatment, enhance the tonic activity of hippocampal 5-HT1A receptors, promote neurogenesis, and modulate (decrease or increase) the firing activity of noradrenergic neurons. Interestingly, cannabinoid agonists and endocannabinoid enhancers increase serotonin and noradrenergic neuronal firing activity, increase serotonin release in the hippocampus, as well as promote neurogenesis. Since cannabinoid-derived drugs potentiate monoaminergic neurotransmission and hippocampal neurogenesis through distinct pathways compared to classical antidepressants, they may represent an alternative drug class in the pharmacotherapy of mood and other neuropsychiatric disorders.
Keywords: Endocannabinoid, cannabinoid CB1 receptor, serotonin, norepinephrine, CB1 agonists and antagonists, antidepressant, fatty acid amide hydrolase (FAAH), URB597
Current Pharmaceutical Design
Title: Endocannabinoids in the Treatment of Mood Disorders: Evidence from Animal Models
Volume: 15 Issue: 14
Author(s): Francis Rodriguez Bambico, Andrea Duranti, Andrea Tontini, Giorgio Tarzia and Gabriella Gobbi
Affiliation:
Keywords: Endocannabinoid, cannabinoid CB1 receptor, serotonin, norepinephrine, CB1 agonists and antagonists, antidepressant, fatty acid amide hydrolase (FAAH), URB597
Abstract: Among all mental disorders, major depression has the highest rate of prevalence and incidence of morbidity. Currently available antidepressant therapies have limited efficacies; consequently, research on new drugs for the treatment of mood disorders has become increasingly critical. Recent preclinical evidences that cannabinoid agonists and endocannabinoid enhancers, such as the fatty acid amide hydrolase (FAAH) inhibitors, can impact mood regulation have opened a new line of research in antidepressant drug discovery. However, the neurobiological mechanisms linking the endocannabinoid system with the pathophysiology of mood disorders and antidepressant action remain unclarified. In this review, we have presented an update on preclinical data indicating the antidepressant potential of cannabinoid agonists and endocannabinoid enhancers in comparison to standard antidepressants. Data obtained from CB1 knockout (CB1-/-) and FAAH knockout (FAAH-/-) mice have also been examined within this context. We have illustrated how the various classes of antidepressants exert their therapeutic action. In particular, all antidepressants increase the neurotransmission of serotonin after long-term treatment, enhance the tonic activity of hippocampal 5-HT1A receptors, promote neurogenesis, and modulate (decrease or increase) the firing activity of noradrenergic neurons. Interestingly, cannabinoid agonists and endocannabinoid enhancers increase serotonin and noradrenergic neuronal firing activity, increase serotonin release in the hippocampus, as well as promote neurogenesis. Since cannabinoid-derived drugs potentiate monoaminergic neurotransmission and hippocampal neurogenesis through distinct pathways compared to classical antidepressants, they may represent an alternative drug class in the pharmacotherapy of mood and other neuropsychiatric disorders.
Export Options
About this article
Cite this article as:
Rodriguez Bambico Francis, Duranti Andrea, Tontini Andrea, Tarzia Giorgio and Gobbi Gabriella, Endocannabinoids in the Treatment of Mood Disorders: Evidence from Animal Models, Current Pharmaceutical Design 2009; 15 (14) . https://dx.doi.org/10.2174/138161209788168029
DOI https://dx.doi.org/10.2174/138161209788168029 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Circadian Rhythms, Melatonin and Depression
Current Pharmaceutical Design Clinical Vignettes: Integrated Care of Cancer Patients by Oncologists and Cardiologists
Current Cardiology Reviews Agomelatine for Bipolar Depression: A Chronotherapeutic Agent?
Current Psychopharmacology Neurovascular Mechanisms of Hypertension in Pregnancy
Current Neurovascular Research Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design Establishment of a Secondary Screening Assay for P/Q-Type Calcium Channel Blockers
Combinatorial Chemistry & High Throughput Screening Preface
Current Drug Research Reviews Repurposing of Copper(II)-chelating Drugs for the Treatment of Neurodegenerative Diseases
Current Medicinal Chemistry Recognition of Nucleic Acids by Toll-Like Receptors and Development of Immunomodulatory Drugs
Current Medicinal Chemistry Cell Biological Consequences of Mitochondrial NADH: Ubiquinone Oxidoreductase Deficiency
Current Neurovascular Research Designing In Vitro Strategies and In Vivo Models for Alzheimer's Disease - Promises & Challenges
Current Alzheimer Research The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson's Disease Model
CNS & Neurological Disorders - Drug Targets Role of Cardiolipin in Mitochondrial Diseases and Apoptosis
Current Medicinal Chemistry Effects of Engineered Type I Collagen on Hepatocyte Cultures
Current Nanoscience Pharmacokinetic Profiles of Anticancer Herbal Medicines in Humans and the Clinical Implications
Current Medicinal Chemistry Analysis of Copy Number Variation in Alzheimer’s Disease: The NIALOAD/ NCRAD Family Study
Current Alzheimer Research Beta-Amyloid, Oxidative Stress and Down Syndrome
Current Alzheimer Research Heme Oxygenase-1 Dysregulation in the Brain: Implications for HIVAssociated Neurocognitive Disorders
Current HIV Research Fibrosis as a Therapeutic Target Post-Myocardial Infarction
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Alzheimer Research